Dianosic

About:

Dianosic aims at resolving patient compliance challenges in respiratory care with intranasal, drug-eluting, resorbable scaffolds

Website: https://dianosic.com/

Twitter/X: dianosicfrance

Top Investors: Bpifrance, WiSEED, Caisse d’Epargne, Banque Populaire Rives de Paris, Fondation Force

Description:

Dianosic was founded in 2017 and develops cutting-edge solutions to resolve patient compliance challenges in Ear, Nose and Throat (ENT) conditions such as chronic allergic rhinitis and chronic sinusitis. Dianosic’s strategic goal is to establish new standards of care in chronic rhinitis and chronic sinusitis with its drug-eluting Active Resorbable Scaffold (ARIS). This breakthrough formulation is developed with world renowned resorbable polymers experts. This long acting (6 to 12 months), steady releasing, patients and physicians' friendly, has the potential to establish new treatment paradigms. Noteworthy, our ARIS platform creates immense opportunities to create other verticals, especially in the field of chronic migraine and facial pain.